Flumethrin + Imidacloprid

Verify with FDA CVM →

350 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
350
Total Reports
6
Deaths Reported
170.0%
Death Rate

Active Ingredients

FlumethrinFlumethrin + ImidaclopridImidacloprid

Administration Routes

TopicalCutaneousUnknownOtherTransdermal

Species Affected

Dog 306
Cat 44

Most Affected Breeds

Retriever - Labrador 38
Crossbred Canine/dog 32
Dog (unknown) 20
Retriever - Golden 18
Terrier - Yorkshire 15
Domestic Shorthair 15
Cat (unknown) 14
Shepherd Dog - German 13
Chihuahua 12
Shih Tzu 10

Most Reported Reactions

Lack of efficacy (ectoparasite) - flea 116
Pruritus 92
Vomiting 38
Lethargy (see also Central nervous system depression in 'Neurological') 34
Behavioural disorder NOS 25
Lack of efficacy (flea) 24
Other abnormal test result NOS 20
Diarrhoea 15
Emesis 14
INEFFECTIVE, HOOKS 13
Lack of efficacy (endoparasite) - heartworm 13
Seizure NOS 12

Outcome Breakdown

Outcome Unknown
209 (59.7%)
Ongoing
78 (22.3%)
Recovered/Normal
53 (15.1%)
Recovered with Sequela
4 (1.1%)
Died
4 (1.1%)
Euthanized
2 (0.6%)

Data Summary

Metric Value
Total adverse event reports 350
Reports involving death 6
Case-fatality rate (reported events) 170.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Flumethrin + Imidacloprid Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 350 adverse event reports referencing Flumethrin + Imidacloprid, including 6 reports in which the animal died — a 170.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Flumethrin, Flumethrin + Imidacloprid, Imidacloprid. Reported administration routes include Topical, Cutaneous, Unknown, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Flumethrin + Imidacloprid reports are Dog (306 reports), Cat (44 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (38), Crossbred Canine/dog (32), Dog (unknown) (20) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Flumethrin + Imidacloprid are Lack of efficacy (ectoparasite) - flea (116), Pruritus (92), Vomiting (38), Lethargy (see also Central nervous system depression in 'Neurological') (34). Of the 350 reports with a coded outcome, Outcome Unknown is the leading category at 59.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Flumethrin + Imidacloprid.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial